1. Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
- Author
-
Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H, and Nakamura T
- Subjects
- Humans, Female, Retrospective Studies, Aged, Middle Aged, Piperazines therapeutic use, Piperazines adverse effects, Piperazines pharmacology, Piperazines administration & dosage, Aminopyridines therapeutic use, Aminopyridines pharmacology, Aminopyridines adverse effects, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors pharmacology, Pyridines therapeutic use, Pyridines pharmacology, Pyridines adverse effects, Pyridines administration & dosage, Benzimidazoles therapeutic use, Benzimidazoles pharmacology, Benzimidazoles adverse effects, Adult, Aged, 80 and over, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Breast Neoplasms pathology, Proton Pump Inhibitors therapeutic use, Proton Pump Inhibitors pharmacology, Proton Pump Inhibitors adverse effects, Proton Pump Inhibitors administration & dosage, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Cyclin-Dependent Kinase 4 antagonists & inhibitors
- Abstract
Background: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment., Patients and Methods: This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio., Results: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Adverse event incidence and severity were similar in both groups., Conclusion: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF